They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

vaccine Gardasil/Gardasil 9, due to reduced demand in China. Gardasil sales fell 17% to $1.550 billion, while FactSet was expecting $1.564 billion. Gardasil had been benefiting from extremely ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck expects to earn $8.88 to $9.03 per share this year ... the issues in China were disclosed last summer. Merck's Gardasil vaccine sales over the quarters Still, sales of Keytruda, the ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

It's the most common sexually transmitted infection, but it's also preventable thanks to the vaccine Gardasil-9. Yet online, misinformation runs rampant about the vaccine, which is also known for ...

Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted ... Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer ...